US SEC Trading Suspension Halt Orders — October 19, 2026

Nasdaq Staff Determination under Rule 5810(c)(3)(A)(iii) after ten consecutive days at or below $0.10 (as of October 14, 2026); suspension and delisting of common stock and warrants effective October 23, 2026

Hearing request will not stay suspension; $20,000 fee and 4:00 p.m. ET October 23 deadline mean any appeal is largely symbolic for near-term trading

CFO Udaychandra Devasper resigned effective October 23, 2026, coinciding with the delisting date, a negative signal on management continuity

Board is exploring headcount reductions, possible suspension of SEC reporting obligations, and strategic alternatives including sale or merger; suspension of SEC reporting would further reduce disclosure and liquidity

Preliminary unaudited Q3 2026 revenue of about $1.22 million, up 256% from roughly $344,000 in Q2 2026, driven by the August 2026 REZENOPY launch and initial wholesale shipments

Arbli wholesale unit sales grew 74% sequentially, showing continued commercial momentum independent of the launch effect

Management targets profitability in 2027, but figures are unaudited and subject to adjustment in the Form 10-Q; treat the inflection as provisional

Going-concern doubt, dilution risk from future funding, and security interests under credit arrangements temper the revenue story

Market value of listed securities deficiency (notice dated April 24, 2026) with compliance deadline October 21, 2026 shows a second Nasdaq standard failing alongside the bid-price test

Trading suspension and delisting of common stock and warrants at the open on October 23, 2026; the March 10, 2027 bid-price compliance deadline is now moot

CFO resignation effective October 23, 2026, the same day as delisting, leaves a financial leadership gap during strategic review

Board considering suspension of SEC reporting obligations, which would reduce transparency for remaining holders and any counterparties in a sale or merger process

No assurance that headcount reduction, strategic alternatives, or a sale or merger will succeed; equity holders face potential total loss

Market value of listed securities deficiency (April 24, 2026 notice) with October 21, 2026 deadline indicates failure of more than one Nasdaq standard

Filing explicitly flags substantial doubt about the ability to continue as a going concern despite the revenue step-up

Future funding may dilute shareholders, and security interests under credit arrangements rank ahead of equity

Filing references Item 3.01 Nasdaq listing notice disclosure, meaning the company itself flags possible delisting exposure

Q3 2026 revenue is preliminary, and the 256% growth figure could be revised in the 10-Q

Revenue of about $1.22 million in Q3 2026 after $344,000 in Q2 shows early launch traction; sustained sequential growth from initial wholesale shipments would validate the 2027 profitability target

74% sequential wholesale unit growth in Arbli provides a second revenue leg that does not depend on the REZENOPY launch

Full audited-quality Q3 results in the Form 10-Q will confirm or revise the preliminary 256% figure, a near-term event that could reprice the stock

Management targets profitability in 2027; if the revenue trajectory holds, the gap between a going-concern profile and profitability narrows meaningfully

Board is exploring strategic alternatives including sale or merger; a distressed-stage delisting can create an acquisition or reverse-merger setup for well-capitalized parties, though no assurance is given

Suspensions of this type often lead to OTC trading with materially different liquidity; a restructuring or merger announcement after October 23 could create a dislocation trade for specialist investors

Stardust Power failed at least two Nasdaq standards (bid price and market value of listed securities) before the accelerated $0.10 trigger, showing that deficiencies typically compound before forced removal

Scienture reports a 256% revenue jump yet still flags going-concern risk, illustrating that early commercial traction in pre-profit life sciences or specialty companies rarely resolves financing stress immediately

Stardust's combination of headcount cuts, possible SEC deregistration, and sale-or-merger exploration reflects a common playbook for microcaps facing delisting, usually with low recovery for public equity holders

Scienture's use of unaudited preliminary results ahead of the 10-Q highlights a trend of companies pre-announcing growth to support listing or financing narratives, requiring investors to discount provisional figures

Trading suspension and delisting at the open on October 23, 2026; monitor whether the company files a hearing request by 4:00 p.m. ET that day

Resignation of Udaychandra Devasper effective October 23, 2026; watch for interim CFO appointment and any 8-K disclosure

Board may suspend SEC reporting obligations; a Form 15 filing would signal deregistration

Any sale, merger, or headcount reduction announcement following delisting

Audited-quality revenue confirmation and any change to the going-concern language

Monitor Item 3.01 developments and any compliance plan submitted to Nasdaq

Watch for equity issuance or credit amendments given the dilution and security-interest disclosures